Logo
Login Sign Up
Current Revision

BSI PD ISO/TS 20399-2:2018

Biotechnology. Ancillary materials present during the production of cellular therapeutic products -- Best practice guidance for ancillary material suppliers
Best Price Guarantee
Instant

$222.36

2-5 Days

$222.36

SAVE 10%

$400.25


Sub Total (1 Item(s))

$ 0.00

Estimated Shipping

$ 0.00

Total (Pre-Tax)

$ 0.00


View in Library
or
British Standards Institution Logo

BSI PD ISO/TS 20399-2:2018

Biotechnology. Ancillary materials present during the production of cellular therapeutic products -- Best practice guidance for ancillary material suppliers

PUBLISH DATE 2018
PAGES 20
BSI PD ISO/TS 20399-2:2018

This document provides guidance for ancillary material (AM) suppliers to maintain a high level of lot-to-lot consistency in the aspects of identity, purity, stability, biosafety, performance, as well as the accompanying documentation.

This document is applicable to cellular therapeutic products, including gene therapy products whereby cells form part of the final product. It does not apply to products without cells.

The AMs described in this document include those of biological origin [e.g. sera, media (including media additives), growth factors, and monoclonal antibodies] and chemical origin. This document does not address dimethyl sulfoxide (DMSO) for cryopreservation, beads, scaffolds, feeder cells, apparatus and instruments, or additives used post bioprocessing.

This document does not cover the selection, assessment or control of starting materials and excipients.

NOTE: International, regional or national regulations or requirements can also apply to specific topics covered in this document.

SDO BSI: British Standards Institution
Document Number ISO/TS 20399-2
Publication Date Dec. 7, 2018
Language en - English
Page Count
Revision Level
Supercedes
Committee BTI/1
Loading...

Failed to load document history.

Publish Date Document Id Type View